Interview to F Peri on new molecules against COVID19 infections (La Repubblica, 28 Marzo 2020)
Read the interview
Watch the inteview
Abstract Next-generation sequencing techniques have enabled identification of the microorganisms colonizing mucosal tissues. The International Congress “MicrobiotaMi 2020” (Milan, February 2020) will focus on the mechanisms of microbiota-related functions in health and disease and their clinical application. Read the paper
Rationale COVID-19 may present with mild, moderate, or severe illness. The severe clinical manifestations include severe pneumonia, Acute Respiratory Syndrome (ARDS), sepsis, and septic shock (Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation and Treatment Coronavirus (COVID-19) [Updated 2020 Mar 8]. In: StatPearls-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/). While the virus itself is only moderately pathogenic and about 50% of infected individuals barely notice (“a bad flu”). The others suffer from
MicrobiotaMi 2020 is coming!!